Skip to main content
SyntekaBio,Inc. logo

SyntekaBio,Inc. — Investor Relations & Filings

Ticker · 226330 ISIN · KR7226330009 KO Professional, scientific and technical activities
Open in API
Filings indexed 322 across all filing types
Latest filing 2025-12-19 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 226330

About SyntekaBio,Inc.

https://www.syntekabio.com/

SyntekaBio is an AI-driven drug discovery company that utilizes its proprietary supercomputing infrastructure, the AI Bio-Supercom Center, to accelerate pharmaceutical development. The company's core technology, the DeepMatcher® platform, underpins a suite of services for discovering small molecules, antibodies, and neoantigens for personalized cancer vaccines. A key offering is LaunchPad, a factory-like system that continuously generates a stream of 'off-the-shelf' drug candidates for numerous disease targets, aiming to expedite the path to IND-enabling studies. SyntekaBio delivers its solutions through comprehensive discovery partnerships and a modular, cloud-based Software as a Service (SaaS) platform, STB CLOUD, providing researchers with automated tools for drug development and genomics analysis.

Recent filings

Filing Released Lang Actions
증권발행실적보고서
Share Issue/Capital Change Classification · 100% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed by Syntekabio. This document is a mandatory regulatory filing in South Korea that details the final results of a capital increase (rights offering), including subscription status, allocation, and use of proceeds. It is not an announcement of a report, but the report itself, detailing the outcome of a financing event. Therefore, it falls under the 'Share Issue/Capital Change' category.
2025-12-19 Korean
유상증자또는주식관련사채등의청약결과(자율공시)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the results of a paid-in capital increase (rights offering and public offering). It details the subscription results, including the number of shares, subscription rates, and future schedules for payment and listing. This falls under the category of capital and financing updates as it directly relates to the company's capital structure changes and fundraising activities.
2025-12-18 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in Korea, which is a regulatory requirement for shareholders who cross certain ownership thresholds or change their holdings significantly. This specific document details the reporting of share collateral agreements (주식담보계약) by the major shareholder, Jung Jong-sun, of Syntekabio. In the context of global financial filings, this falls under the category of 'Major Shareholding Notification' (MRQ), as it tracks changes in significant share ownership and related contractual obligations.
2025-12-17 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) by Syntekabio. It details the contract value, counterparty, duration, and payment terms. Since this is a specific regulatory disclosure regarding a business contract that does not fit into the other specialized categories like M&A or financial reports, it falls under the general regulatory filing category.
2025-12-17 Korean
투자판단관련주요경영사항 (Ab-ARS™플랫폼으로 발굴한 항암 및 면역질환 항체 후보물질 기술이전)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (Syntekabio) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically detailing a technology transfer agreement (licensing deal) for antibody candidates. This type of disclosure regarding business contracts, partnerships, or licensing deals is classified as a general regulatory filing (RNS) in the absence of a more specific category like M&A or capital change.
2025-12-16 Korean
유상증자1차발행가액결정
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the determination of the first issuance price for a rights offering (유상증자 1차발행가액 결정). It details the number of shares to be issued, the price per share, the calculation method for the issuance price, and the schedule for finalizing the price. This is clearly an update on the company's capital raising activity and changes to its capital structure. The document is relatively short (2290 characters) and focuses on the pricing and terms of a share issuance, not a full financial report or other type of filing. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-11-05 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.